Business
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
– Clinical Data Include Analyses of Novel, Investigational Long-acting Therapies and Combination Cure Strategy Research with the Potential to Help Address
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n– Clinical Data Include Analyses of Novel, Investigational Long-acting Therapies and Combination Cure Strategy Research with the Potential to Help Address the Diverse and Unmet Needs of People with HIV –\n\n– Real-World Evidence Evaluating the Effectiveness of Veklury in Broad Range of Hospitalized Patient Populations Being Presented, Including Those at High Risk for COVID-19 Disease Progression –\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new clinical and real-world data from the company’s HIV, COVID-19 and viral hepatitis research and development programs at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) from February 19-22. Seventy abstracts, including late-breaking data, demonstrate Gilead’s continued expertise and leadership in virology with a commitment to advance the next wave of scientific discovery to treat, prevent, cure and help eradicate viral diseases.\n\n“Positioning people at the center of the research and development process is helping us to fuel the next wave of innovation in virology,” said Frank Duff, MD, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences. “Our scientific advances are grounded in collaboration with community and research partners around the world and highlight the importance of developing innovative solutions for the unmet and evolving needs of those most affected by viral diseases. The data selected for presentation at CROI include real-world evidence in the treatment of COVID-19, the investigational evaluation of existing therapies for HIV/hepatitis B co-infection, and new HIV treatment, prevention, and cure data evaluating long-acting options as well as novel combination therapies.”\n\nHIV Research\n\nGilead is committed to continuous scientific discovery to provide solutions for the evolving needs of people affected by HIV around the world, with the goal of ending the HIV epidemic for everyone, everywhere. At CROI 2023, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company’s continued pursuit of an HIV cure.\n\nHIV treatment research and development data include proof-of-concept Phase 1b data on the safety and efficacy profile of lenacapavir in combination with investigational broadly neutralizi...